Vertex reports third quarter 2024 financial results

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today reported consolidated financial results for the third quarter ended september 30, 2024, and raised its full-year product revenue guidance to $10.8 billion to $10.9 billion. “the third quarter marked another period of strong progress, with continued revenue growth and outstanding execution across the business, and we are again increasing our full-year product revenue guidance,” said reshma kewalramani, m.d., chief.
VRTX Ratings Summary
VRTX Quant Ranking